Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.

Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T.

Cancer Sci. 2019 Aug 7. doi: 10.1111/cas.14165. [Epub ahead of print]

2.

Immunological consequences following splenectomy in patients with liver cirrhosis.

Hirakawa Y, Ogata T, Sasada T, Yamashita T, Itoh K, Tanaka H, Okuda K.

Exp Ther Med. 2019 Jul;18(1):848-856. doi: 10.3892/etm.2019.7640. Epub 2019 Jun 3.

3.

Prospects for a personalized peptide vaccine against lung cancer.

Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T.

Expert Rev Vaccines. 2019 Jul;18(7):703-709. doi: 10.1080/14760584.2019.1635461. Epub 2019 Jun 28.

PMID:
31225971
4.

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy.

Matsuo N, Azuma K, Sasada T.

Oncotarget. 2019 Mar 8;10(20):1866-1867. doi: 10.18632/oncotarget.26749. eCollection 2019 Mar 8. No abstract available.

5.

[A Case of Laparoscopic Abdominoperineal Resection of Anorectal Malignant Melanoma].

Okuda H, Nakahara M, Yano T, Bekki T, Hirohata R, Hakoda K, Hirata F, Abe T, Fujikuni N, Sasada T, Yamaki M, Amano H, Noriyuki T.

Gan To Kagaku Ryoho. 2019 Mar;46(3):573-575. Japanese.

PMID:
30914618
6.

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.

Iiizumi S, Ohtake J, Murakami N, Kouro T, Kawahara M, Isoda F, Hamana H, Kishi H, Nakamura N, Sasada T.

Cancers (Basel). 2019 Feb 24;11(2). pii: E266. doi: 10.3390/cancers11020266.

7.

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M.

Neuro Oncol. 2019 Feb 19;21(3):348-359. doi: 10.1093/neuonc/noy200.

PMID:
30500939
8.

Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.

Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T.

Oncotarget. 2018 Sep 25;9(75):34066-34078. doi: 10.18632/oncotarget.26122. eCollection 2018 Sep 25.

9.

Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.

Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T.

Int J Cancer. 2019 Mar 1;144(5):1170-1179. doi: 10.1002/ijc.31923. Epub 2018 Nov 12.

PMID:
30307035
10.
11.

Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer.

Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, Shirabe K, Kuwano H, Yamaue H.

Oncotarget. 2018 Jul 31;9(59):31448-31458. doi: 10.18632/oncotarget.25837. eCollection 2018 Jul 31.

12.

Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.

Ono T, Azuma K, Kawahara A, Sasada T, Matsuo N, Kakuma T, Kamimura H, Maeda R, Hattori C, On K, Nagata K, Sato F, Chitose SI, Shin B, Aso T, Akiba J, Umeno H.

Head Neck. 2018 Sep;40(9):2007-2019. doi: 10.1002/hed.25189. Epub 2018 May 13.

PMID:
29756253
13.

Use of patient-derived xenograft mouse models in cancer research and treatment.

Yada E, Wada S, Yoshida S, Sasada T.

Future Sci OA. 2017 Dec 7;4(3):FSO271. doi: 10.4155/fsoa-2017-0136. eCollection 2018 Mar. No abstract available.

14.

[Twenty-Five Cases of Locally Advanced Rectal Cancer That Underwent Laparoscopic Surgery after Preoperative Chemotherapy].

Okuda H, Nakahara M, Yano T, Bekki T, Takechi H, Yoshikawa T, Mochizuki T, Abe T, Fujikuni N, Sasada T, Yamaki M, Amano H, Noriyuki T.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1772-1774. Japanese.

PMID:
29394771
15.

Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.

Ono T, Azuma K, Kawahara A, Sasada T, Hattori S, Sato F, Shin B, Chitose SI, Akiba J, Hirohito U.

Oncotarget. 2017 Oct 6;8(54):92699-92714. doi: 10.18632/oncotarget.21564. eCollection 2017 Nov 3.

16.

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.

Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T.

Oncotarget. 2017 Jun 27;8(37):61618-61625. doi: 10.18632/oncotarget.18651. eCollection 2017 Sep 22.

17.

Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.

Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M.

Cancer Sci. 2017 Dec;108(12):2430-2437. doi: 10.1111/cas.13404. Epub 2017 Oct 12.

18.

Are peptide vaccines viable in combination with other cancer immunotherapies?

Ohtake J, Sasada T.

Future Oncol. 2017 Aug;13(18):1577-1580. doi: 10.2217/fon-2017-0136. Epub 2017 Aug 4. No abstract available.

PMID:
28776424
19.

Complete torsion of gallbladder following laparoscopic cholecystectomy: A case study.

Bekki T, Abe T, Amano H, Fujikuni N, Okuda H, Sasada T, Yamaki M, Kobayashi T, Noriyuki T, Nakahara M.

Int J Surg Case Rep. 2017;37:257-260. doi: 10.1016/j.ijscr.2017.06.051. Epub 2017 Jun 29.

20.

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.

Yutani S, Shirahama T, Muroya D, Matsueda S, Yamaguchi R, Morita M, Shichijo S, Yamada A, Sasada T, Itoh K.

Cancer Sci. 2017 Sep;108(9):1732-1738. doi: 10.1111/cas.13301. Epub 2017 Jul 23.

21.

Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.

Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T.

Clin Lung Cancer. 2017 Nov;18(6):e385-e394. doi: 10.1016/j.cllc.2017.03.011. Epub 2017 Mar 24.

22.

Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females.

Yokomine M, Matsueda S, Kawano K, Sasada T, Fukui A, Yamashita T, Komatsu N, Shichijo S, Tasaki K, Matsukuma K, Itoh K, Kamura T, Ushijima K.

Exp Ther Med. 2017 Apr;13(4):1500-1505. doi: 10.3892/etm.2017.4150. Epub 2017 Feb 21.

23.

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13.

24.

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.

Shirahama T, Muroya D, Matsueda S, Yamada A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K, Sasada T, Yutani S.

Cancer Sci. 2017 May;108(5):838-845. doi: 10.1111/cas.13193. Epub 2017 May 5.

25.

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K.

Cancer Sci. 2017 Apr;108(4):598-603. doi: 10.1111/cas.13189. Epub 2017 Apr 21.

26.

Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations.

Sasada T.

Nihon Rinsho. 2017 Feb;75(2):189-195. Review. Japanese.

PMID:
30562851
27.

Optimizing outcomes in clozapine rechallenge following neutropenia using human leukocyte antigen typing: A case report.

Yamaki N, Hishimoto A, Otsuka I, Sasada T, Boku S, Saito T, Yasuda Y, Yamamori H, Ikeda M, Ikeda M, Sora I, Iwata N, Hashimoto R.

Psychiatry Clin Neurosci. 2017 Apr;71(4):289-290. doi: 10.1111/pcn.12505. Epub 2017 Mar 11. No abstract available.

28.

Current status and future prospects of peptide-based cancer vaccines.

Wada S, Yada E, Ohtake J, Fujimoto Y, Uchiyama H, Yoshida S, Sasada T.

Immunotherapy. 2016 Nov;8(11):1321-1333. Review.

PMID:
27993087
29.

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment.

Sasada T, Azuma K, Ohtake J, Fujimoto Y.

Front Pharmacol. 2016 Oct 26;7:405. eCollection 2016. Review.

30.

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.

Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, Yamada A, Noguchi M, Itoh K, Nakanishi Y.

J Immunol Res. 2016;2016:1745108. doi: 10.1155/2016/1745108. Epub 2016 May 4.

31.

Late-onset diaphragmatic hernia after percutaneous radiofrequency ablation of hepatocellular carcinoma: a case study.

Abe T, Amano H, Takechi H, Fujikuni N, Sasada T, Yoshida M, Yamaki M, Nakahara M, Noriyuki T.

Surg Case Rep. 2016 Dec;2(1):25. doi: 10.1186/s40792-016-0148-3. Epub 2016 Mar 14.

32.

Prospect and progress of personalized peptide vaccinations for advanced cancers.

Sakamoto S, Noguchi M, Yamada A, Itoh K, Sasada T.

Expert Opin Biol Ther. 2016;16(5):689-98. doi: 10.1517/14712598.2016.1161752. Epub 2016 Mar 21. Review.

PMID:
26938083
33.

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.

Iwasa S, Yamada Y, Heike Y, Shoji H, Honma Y, Komatsu N, Matsueda S, Yamada A, Morita M, Yamaguchi R, Tanaka N, Kawahara A, Kage M, Shichijo S, Sasada T, Itoh K.

Cancer Sci. 2016 May;107(5):590-600. doi: 10.1111/cas.12919. Epub 2016 Apr 26.

34.

Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.

Curry WT Jr, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G.

Clin Cancer Res. 2016 Jun 15;22(12):2885-96. doi: 10.1158/1078-0432.CCR-15-2163. Epub 2016 Feb 12.

35.

[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination].

Takemoto Y, Noriyuki T, Takei D, Kawashima M, Saito R, Ono N, Sasada T, Yoshida M, Yamaki M, Amano H, Fukuda T, Nakahara M.

Gan To Kagaku Ryoho. 2016 Jan;43(1):121-4. Japanese.

PMID:
26809539
36.

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.

Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K.

Cancer Immunol Immunother. 2016 Feb;65(2):151-60. doi: 10.1007/s00262-015-1781-6. Epub 2016 Jan 4.

PMID:
26728480
37.

Primary Large-Cell Neuroendocrine Carcinoma of the Breast Occurring in a Pre-Menopausal Woman.

Yoshimura N, Sasada T, Yonehara S.

Breast Care (Basel). 2015 Aug;10(4):281-3. doi: 10.1159/000431070. Epub 2015 May 29.

38.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

39.

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.

Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K.

Clin Cancer Res. 2016 Jan 1;22(1):54-60. doi: 10.1158/1078-0432.CCR-15-1265. Epub 2015 Nov 18.

40.

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.

Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M.

J Immunol Res. 2015;2015:473909. doi: 10.1155/2015/473909. Epub 2015 Oct 11.

41.

Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.

Araki H, Pang X, Komatsu N, Soejima M, Miyata N, Takaki M, Muta S, Sasada T, Noguchi M, Koda Y, Itoh K, Kuhara S, Tashiro K.

Cancer Immunol Immunother. 2015 Dec;64(12):1565-73. doi: 10.1007/s00262-015-1756-7. Epub 2015 Oct 1.

PMID:
26428930
42.

Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.

Kawaguchi Y, Hinoi T, Saito Y, Adachi T, Miguchi M, Niitsu H, Sasada T, Shimomura M, Egi H, Oka S, Tanaka S, Chayama K, Sentani K, Oue N, Yasui W, Ohdan H.

J Gastroenterol. 2016 May;51(5):447-57. doi: 10.1007/s00535-015-1121-9. Epub 2015 Sep 11.

PMID:
26361962
43.

[Localized Malignant Mesothelioma of the Pleura].

Takei D, Yamaki M, Noriyuki T, Takemoto Y, Kawashima M, Saito R, Sasada T, Yoshida M, Amano H, Fukuda T, Nakahara M.

Kyobu Geka. 2015 Aug;68(9):761-3. Japanese.

PMID:
26329709
44.

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination.

Sakamoto S, Yoshitomi M, Yutani S, Terazaki Y, Yoshiyama K, Ioji T, Matsueda S, Yamada A, Takamori S, Itoh K, Hattori N, Kohno N, Sasada T.

Hum Vaccin Immunother. 2015;11(12):2784-9. doi: 10.1080/21645515.2015.1075107.

45.

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K.

Cancer Sci. 2015 Oct;106(10):1257-63. doi: 10.1111/cas.12757. Epub 2015 Sep 25.

46.

Chlorinated Water Modulates the Development of Colorectal Tumors with Chromosomal Instability and Gut Microbiota in Apc-Deficient Mice.

Sasada T, Hinoi T, Saito Y, Adachi T, Takakura Y, Kawaguchi Y, Sotomaru Y, Sentani K, Oue N, Yasui W, Ohdan H.

PLoS One. 2015 Jul 17;10(7):e0132435. doi: 10.1371/journal.pone.0132435. eCollection 2015.

47.

Personalized peptide vaccination for advanced colorectal cancer.

Sasada T, Kibe S, Akagi Y, Itoh K.

Oncoimmunology. 2015 Feb 3;4(5):e1005512. eCollection 2015 May.

48.

Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.

Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S, Komatsu N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K.

Cancer Immunol Immunother. 2015 Apr;64(4):493-505. doi: 10.1007/s00262-015-1660-1. Epub 2015 Feb 7.

PMID:
25662406
49.

[Pulmonary dirofilariasis].

Takei D, Yamaki M, Noriyuki T, Takemoto Y, Kawashima M, Saitoh R, Sasada T, Yoshida M, Amano H, Fukuda T, Nakahara M, Masuda K.

Kyobu Geka. 2015 Jan;68(1):76-9. Japanese.

PMID:
25595164
50.

The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial.

Shigematsu H, Kadoya T, Masumoto N, Sasada T, Emi A, Ohara M, Kajitani K, Okada M.

Clin Breast Cancer. 2015 Apr;15(2):110-6. doi: 10.1016/j.clbc.2014.09.010. Epub 2014 Oct 2.

PMID:
25454688

Supplemental Content

Loading ...
Support Center